RxDoctor Payments DataLook up a doctor →

Charles Wykoff, MD

Ophthalmology · Bellaire, TXNPI 1124237300

Payments from drug & device makers

$73,415,283in general payments, 2019–2025

Across 4,601 payments — averaging $15,956 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$29.2M
  • Genentech, Inc.$27.1M
  • Regeneron$9.6M
  • Bayer$1.4M
  • Apellis Pharmaceuticals, Inc.$1.1M
  • Ocular Therapeutix, Inc.$906K
  • plus $4.2M from 49 others
$117,454in research payments, 2019–2025

Across 60 payments — averaging $1957.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$48K
  • Regeneron$28K
  • Novartis$14K
  • Ocular Therapeutix, Inc.$11K
  • Novartis Pharma AG$9K
  • Alimera Sciences, Inc.$7K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis78$29,222,262
Genentech, Inc.864$27,083,417
Regeneron1,642$9,618,029
Bayer436$1,354,646
Apellis Pharmaceuticals, Inc.221$1,057,780
Ocular Therapeutix, Inc.99$905,657
Boehringer Ingelheim72$759,510
Boehringer Ingelheim International GmbH427$669,055
AstraZeneca4$649,948
Eyepoint US, Inc.26$226,816
Kyowa Kirin, Inc.100$223,790
Janssen Research & Development, LLC59$217,525
Roche TCRC, Inc.25$189,264
AbbVie(2 entities)106$187,999
Neurotech Pharmaceuticals, Inc.28$163,898
Novartis Pharma AG24$102,246
Regeneron Healthcare Solutions, Inc.79$101,473
Takeda Pharmaceuticals U.S.A., Inc.4$78,781
Topcon Healthcare, Inc.10$70,165
Oyster Point Pharma, Inc.15$57,849
Sanofi US Services Inc.10$56,917
F. Hoffmann-la Roche AG31$56,161
ANI Pharmaceuticals, Inc.11$43,399
Astellas Pharma Global Development12$40,237
Merck31$34,230
Boehringer Ingelheim Finland Ky34$25,851
Hexal AG7$23,675
Janssen Global Services, LLC13$19,558
GSK4$19,159
Alimera Sciences, Inc.10$18,548
Alcon13$18,067
Aerie Pharmaceuticals, Inc.7$15,748
Genentech USA, Inc.19$15,385
Grifols, S.A.6$14,600
Amgen(2 entities)4$9,763
Shire North American Group Inc4$8,574
Bausch & Lomb Americas Inc.13$8,078
Bausch & Lomb, A Division Of Bausch Health US, LLC8$7,977
Hoffmann-la Roche Limited4$6,450
Alcon Research LLC6$5,551
Kowa Research Institute, Inc.2$4,500
Biocryst Pharmaceuticals, Inc.4$4,499
Astellas Pharma US Inc4$3,834
Thrombogenics, Inc.2$3,750
Alnylam Pharmaceuticals Inc.1$3,640
Samsung Bioepis Co., Ltd.2$2,400
Johnson & Johnson1$1,815
Carl Zeiss Meditec, Inc.2$880
Harrow Eye, LLC1$700
Dutch Ophthalmic, USA1$500
Avirmax Biopharma, Inc3$321
Biogen8$174
Coherus Oncology, Inc.2$133
Spark Therapeutics, Inc.1$82
Mallinckrodt Enterprises LLC1$16

How this compares

$73,415,283 in reported general payments places this provider in the 95th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas →

Medicare billing

Part B allowed, 2024
$7,570,131
Medicare patients
1,160
Services billed
42,254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other ophthalmology in Bellaire

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →